KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Other Non Operating Income: 2012-2024

Historic Other Non Operating Income for Ionis Pharmaceuticals (IONS) over the last 11 years, with Dec 2024 value amounting to $1.3 million.

  • Ionis Pharmaceuticals' Other Non Operating Income rose 155.63% to $363,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 12.89%. This contributed to the annual value of $1.3 million for FY2024, which is 90.58% down from last year.
  • As of FY2024, Ionis Pharmaceuticals' Other Non Operating Income stood at $1.3 million, which was down 90.58% from $14.3 million recorded in FY2023.
  • Over the past 5 years, Ionis Pharmaceuticals' Other Non Operating Income peaked at $14.3 million during FY2023, and registered a low of -$9.8 million during FY2021.
  • Moreover, its 3-year median value for Other Non Operating Income was $1.3 million (2024), whereas its average is $2.8 million.
  • Per our database at Business Quant, Ionis Pharmaceuticals' Other Non Operating Income crashed by 15,641.94% in 2021 and then spiked by 295.99% in 2023.
  • Over the past 5 years, Ionis Pharmaceuticals' Other Non Operating Income (Yearly) stood at -$62,000 in 2020, then plummeted by 15,641.94% to -$9.8 million in 2021, then rose by 25.47% to -$7.3 million in 2022, then surged by 295.99% to $14.3 million in 2023, then crashed by 90.58% to $1.3 million in 2024.